|
1
|
GBD 2016 Brain and Other CNS Cancer
Collaborators: Global, regional, and national burden of brain and
other CNS cancer, 1990–2016: A systematic analysis for the global
burden of disease study 2016. Lancet Neurol. 18:376–393. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weller M, Wick W, Aldape K, Brada M,
Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R and
Reifenberger G: Glioma. Nat Rev Dis Primers. 1:150172015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma R, Taphoorn MJB and Plaha P: Advances
in the management of glioblastoma. J Neurol Neurosurg Psychiatry.
92:1103–1111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang T, Nam DH, Ram Z, Poon WS, Wang J,
Boldbaatar D, Mao Y, Ma W, Mao Q, You Y, et al: Clinical practice
guidelines for the management of adult diffuse gliomas. Cancer
Lett. 499:60–72. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Brada M, van den Bent MJ, Tonn JC
and Pentheroudakis G; ESMO Guidelines Working Group. High-grade
glioma, : ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii93–iii101.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Pineros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daumas-Duport C, Scheithauer B, O'Fallon J
and Kelly P: Grading of astrocytomas. A simple and reproducible
method. Cancer. 62:2152–2165. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cancer Genome Atlas Research Network, .
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LAD,
Rheinbay E, Miller CR, Vitucci M, et al: Comprehensive, integrative
genomic analysis of diffuse lower-grade gliomas. N Engl J Med.
372:2481–2498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stummer W, Meinel T, Ewelt C, Martus P,
Jakobs O, Felsberg J and Reifenberger G: Prospective cohort study
of radiotherapy with concomitant and adjuvant temozolomide
chemotherapy for glioblastoma patients with no or minimal residual
enhancing tumor load after surgery. J Neurooncol. 108:89–97. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jain RK, Martin JD and Stylianopoulos T:
The role of mechanical forces in tumor growth and therapy. Annu Rev
Biomed Eng. 16:321–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang P, Wang Y, Peng X, You G, Zhang W,
Yan W, Bao Z, Wang Y, Qiu X and Jiang T: Management and survival
rates in patients with glioma in China (2004–2010): A retrospective
study from a single-institution. J Neurooncol. 113:259–266. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang S, Wu W, Lin X, Zhang KM, Wu Q, Luo M
and Zhou J: Predictive and prognostic biomarkers of bone metastasis
in breast cancer: Current status and future directions. Cell
Biosci. 13:2242023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greer SN, Metcalf JL, Wang Y and Ohh M:
The updated biology of hypoxia-inducible factor. EMBO J.
31:2448–2460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kenneth NS and Rocha S: Regulation of gene
expression by hypoxia. Biochem J. 414:19–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iyer NV, Kotch LE, Agani F, Leung SW,
Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY
and Semenza GL: Cellular and developmental control of O2
homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev.
12:149–162. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Semenza GL: Hypoxia-inducible factors in
physiology and medicine. Cell. 148:399–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Polyak K, Haviv I and Campbell IG:
Co-evolution of tumor cells and their microenvironment. Trends
Genet. 25:30–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okada M, Saio M, Kito Y, Ohe N, Yano H,
Yoshimura S, Iwama T and Takami T: Tumor-associated
macrophage/microglia infiltration in human gliomas is correlated
with MCP-3, but not MCP-1. Int J Oncol. 34:1621–1627.
2009.PubMed/NCBI
|
|
24
|
Platten M, Kretz A, Naumann U, Aulwurm S,
Egashira K, Isenmann S and Weller M: Monocyte chemoattractant
protein-1 increases microglial infiltration and aggressiveness of
gliomas. Ann Neurol. 54:388–392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reuss AM, Groos D, Buchfelder M and
Savaskan N: The acidic brain-glycolytic switch in the
microenvironment of malignant glioma. Int J Mol Sci. 22:55182021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Palazon A, Goldrath AW, Nizet V and
Johnson RS: HIF transcription factors, inflammation, and immunity.
Immunity. 41:518–528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanehisa M and Goto S: KEGG: kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bindea G, Mlecnik B, Tosolini M,
Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T,
Lafontaine L, Berger A, et al: Spatiotemporal dynamics of
intratumoral immune cells reveal the immune landscape in human
cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ceccarelli M, Barthel FP, Malta TM,
Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh
A, Pagnotta SM, et al: Molecular profiling reveals biologically
discrete subsets and pathways of progression in diffuse glioma.
Cell. 164:550–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alba AC, Agoritsas T, Walsh M, Hanna S,
Iorio A, Devereaux PJ, McGinn T and Guyatt G: Discrimination and
calibration of clinical prediction models: Users' guides to the
medical literature. JAMA. 318:1377–1384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deng B, Zhu JM, Wang Y, Liu TT, Ding YB,
Xiao WM, Lu GT, Bo P and Shen XZ: Intratumor hypoxia promotes
immune tolerance by inducing regulatory T cells via TGF-β1 in
gastric cancer. PLoS One. 8:e637772013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liao Y, Luo Z, Lin Y, Chen H, Chen T, Xu
L, Orgurek S, Berry K, Dzieciatkowska M, Reisz JA, et al: PRMT3
drives glioblastoma progression by enhancing HIF1A and glycolytic
metabolism. Cell Death Dis. 13:9432022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding XC, Wang LL, Zhang XD, Xu JL, Li PF,
Liang H, Zhang XB, Xie L, Zhou ZH, Yang J, et al: The relationship
between expression of PD-L1 and HIF-1α in glioma cells under
hypoxia. J Hematol Oncol. 14:922021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang P, Wan W, Xiong S, Wang J, Zou D, Lan
C, Yu S, Liao B, Feng H and Wu N: HIF1α regulates glioma
chemosensitivity through the transformation between differentiation
and dedifferentiation in various oxygen levels. Sci Rep.
7:79652017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tachibana KE, Gonzalez MA and Coleman N:
Cell-cycle-dependent regulation of DNA replication and its
relevance to cancer pathology. J Pathol. 205:123–129. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen J, Xia Y, Peng Y, Wu S, Liu W, Zhang
H, Wang T, Yang Z, Zhao S and Zhao L: Analysis of the association
between KIN17 expression and the clinical features/prognosis of
epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells.
Oncol Lett. 21:4752021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Forde PM, Chaft JE, Smith KN, Anagnostou
V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR,
Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung
cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leighl NB, Hellmann MD, Hui R, Carcereny
E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L,
et al: Pembrolizumab in patients with advanced non-small-cell lung
cancer (KEYNOTE-001): 3-year results from an open-label, phase 1
study. Lancet Respir Med. 7:347–357. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rini BI, Powles T, Atkins MB, Escudier B,
McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL,
et al: Atezolizumab plus bevacizumab versus sunitinib in patients
with previously untreated metastatic renal cell carcinoma
(IMmotion151): A multicentre, open-label, phase 3, randomised
controlled trial. Lancet. 393:2404–2415. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Colegio OR, Chu NQ, Szabo AL, Chu T,
Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC,
Phillips GM, et al: Functional polarization of tumour-associated
macrophages by tumour-derived lactic acid. Nature. 513:559–563.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dang EV, Barbi J, Yang HY, Jinasena D, Yu
H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al: Control of
T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell.
146:772–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Doedens AL, Phan AT, Stradner MH, Fujimoto
JK, Nguyen JV, Yang E, Johnson RS and Goldrath AW:
Hypoxia-inducible factors enhance the effector responses of CD8(+)
T cells to persistent antigen. Nat Immunol. 14:1173–1182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mascanfroni ID, Takenaka MC, Yeste A,
Patel B, Wu Y, Kenison JE, Siddiqui S, Basso AS, Otterbein LE,
Pardoll DM, et al: Metabolic control of type 1 regulatory T cell
differentiation by AHR and HIF1-alpha. Nat Med. 21:638–646. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li MO, Wolf N, Raulet DH, Akkari L, Pittet
MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S and
Bhardwaj N: Innate immune cells in the tumor microenvironment.
Cancer Cell. 39:725–729. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shaul ME and Fridlender ZG:
Tumour-associated neutrophils in patients with cancer. Nat Rev Clin
Oncol. 16:601–620. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tian S, Chu Y, Hu J, Ding X, Liu Z, Fu D,
Yuan Y, Deng Y, Wang G, Wang L and Wang Z: Tumour-associated
neutrophils secrete AGR2 to promote colorectal cancer metastasis
via its receptor CD98hc-xCT. Gut. 71:2489–2501. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liang J, Piao Y, Holmes L, Fuller GN,
Henry V, Tiao N and de Groot JF: Neutrophils promote the malignant
glioma phenotype through S100A4. Clin Cancer Res. 20:187–198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lanier LL: NK cell recognition. Annu Rev
Immunol. 23:225–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Saulep-Easton D, Vincent FB, Le Page M,
Wei A, Ting SB, Croce CM, Tam C and Mackay F: Cytokine-driven loss
of plasmacytoid dendritic cell function in chronic lymphocytic
leukemia. Leukemia. 28:2005–2015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Michel T, Poli A, Cuapio A, Briquemont B,
Iserentant G, Ollert M and Zimmer J: Human CD56bright NK cells: An
update. J Immunol. 196:2923–2931. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Montaldo E, Vacca P, Moretta L and Mingari
MC: Development of human natural killer cells and other innate
lymphoid cells. Semin Immunol. 26:107–113. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Goodman A, Patel SP and Kurzrock R:
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev
Clin Oncol. 14:203–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Krummel MF and Allison JP: CTLA-4
engagement inhibits IL-2 accumulation and cell cycle progression
upon activation of resting T cells. J Exp Med. 183:2533–2540. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Long GV, Weber JS, Larkin J, Atkinson V,
Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil
C, et al: Nivolumab for patients with advanced melanoma treated
beyond progression: Analysis of 2 phase 3 clinical trials. JAMA
Oncol. 3:1511–1519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
El-Naggar AM, Veinotte CJ, Cheng H,
Grunewald TG, Negri GL, Somasekharan SP, Corkery DP, Tirode F,
Mathers J, Khan D, et al: Translational activation of HIF1α by YB-1
promotes sarcoma metastasis. Cancer Cell. 27:682–697. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu ZJ, Semenza GL and Zhang HF:
Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang
Univ Sci B. 16:32–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xu J, Yang X, Deng Q, Yang C, Wang D,
Jiang G, Yao X, He X, Ding J, Qiang J, et al: TEM8 marks
neovasculogenic tumor-initiating cells in triple-negative breast
cancer. Nat Commun. 12:44132021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Qiao K, Liu Y, Xu Z, Zhang H, Zhang H,
Zhang C, Chang Z, Lu X, Li Z, Luo C, et al: RNA m6A methylation
promotes the formation of vasculogenic mimicry in hepatocellular
carcinoma via Hippo pathway. Angiogenesis. 24:83–96. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yue WY and Chen ZP: Does vasculogenic
mimicry exist in astrocytoma? J Histochem Cytochem. 53:997–1002.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Huang M, Ke Y, Sun X, Yu L, Yang Z, Zhang
Y, Du M, Wang J, Liu X and Huang S: Mammalian target of rapamycin
signaling is involved in the vasculogenic mimicry of glioma via
hypoxia-inducible factor-1alpha. Oncol Rep. 32:1973–1980. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Li J, Ke Y, Huang M, Huang S and Liang Y:
Inhibitory effects of B-cell lymphoma 2 on the vasculogenic mimicry
of hypoxic human glioma cells. Exp Ther Med. 9:977–981. 2015.
View Article : Google Scholar : PubMed/NCBI
|
